Home » Topics » BioWorld Science

BioWorld Science
RSS

EntreMed: Q2 1997 highlights

Aug. 20, 1997

Merck KGaA begins development of cardioprotectant

Aug. 20, 1997

Boston Life Sciences completes phase III trial of Therafectin

Aug. 20, 1997

Antidiabetic herbomineral formulation tested in Indian patients

Aug. 20, 1997

Rapid-acting insulin analog under clinical evaluation

Aug. 20, 1997

Imidazoline derivative displays potent antidiabetic effects in rats

Aug. 20, 1997

Digestive tract marker evaluated in diabetic patients with gastroenteropathies

Aug. 20, 1997

DPP-IV inhibition in the treatment of diabetes

Aug. 20, 1997

Repaglinide gets expedited review status in U.S

Aug. 20, 1997

Oxis granted patent application allowance for ergothioneine analogs

Aug. 20, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Recombinant vaccine inhibits HBV-associated HCC growth
BioWorld Science
Chronic liver disease and hepatocellular carcinoma (HCC) associated with chronic hepatitis B virus (HBV) are serious health problems in highly endemic areas....